series-b
Stage
1
Investors
About
Pulmatrix develops inhaled therapies for respiratory diseases by formulating small-molecule drugs into inhalable dry powders using its iSPERSE particle-engineering technology to enable targeted pulmonary delivery.
Explore Pulmatrix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.